China National Health Commission

China National Health Commission
Agency name	China National Health Commission
Native name	国家卫生健康委员会
Formed	2018
Preceding1	National Health and Family Planning Commission
Jurisdiction	People's Republic of China
Headquarters	Beijing
Chief1 name	Ma Xiaowei
Chief1 position	Minister
Parent agency	State Council

China National Health Commission is the central administrative agency responsible for health administration, medical services, disease prevention, and health policy in the People's Republic of China. It was established in 2018 as part of a broader institutional reform affecting the State Council (China), succeeding the National Health and Family Planning Commission. The commission coordinates national strategies across public institutions, provincial health authorities, and research entities.

History

The commission's origins trace to reforms following the SARS outbreak that influenced the formation of the Ministry of Health (China) and later the National Health and Family Planning Commission. Major reorganizations occurred under the leadership of Li Keqiang and directives from the 13th National People's Congress and the Central Committee of the Chinese Communist Party. Creation in 2018 consolidated functions from the National Health and Family Planning Commission and absorbed responsibilities previously held by the National Administration of Traditional Chinese Medicine and parts of the National Population and Family Planning Commission. The commission's establishment paralleled administrative changes announced by Premier Li Keqiang and endorsed by the State Council (China) during broader efforts to streamline state organs.

Organization and Leadership

The commission is administered under the State Council (China) and led by a minister-level official, with deputies overseeing divisions for public health, medical administration, and global health. Senior personnel have included officials who formerly worked in the Ministry of Health (China), National Health and Family Planning Commission, and provincial health commissions such as the Beijing Municipal Health Commission and Shanghai Municipal Health Commission. Its internal bureaus coordinate with national institutions like the Chinese Center for Disease Control and Prevention and academic bodies such as the Chinese Academy of Medical Sciences and Peking University Health Science Center. Leadership appointments are subject to review by the Central Committee of the Chinese Communist Party and the National People's Congress.

Functions and Responsibilities

The commission formulates national policies on health care, supervises medical service quality, and administers disease surveillance and prevention programs in coordination with the Chinese Center for Disease Control and Prevention, the World Health Organization, and provincial health authorities. It oversees licensing for hospitals including tiers like Tier 3 hospitals (China) and manages regulation of pharmaceuticals, medical devices, and traditional medicine practiced under the National Administration of Traditional Chinese Medicine. Responsibilities include maternal and child health initiatives linked to agencies such as the National Health Commission's predecessors and demographic policy coordination with entities formerly in the National Population and Family Planning Commission.

Policies and Programs

The commission has implemented policies addressing universal healthcare coverage expansion, essential medicine lists, and reforms in public hospital management influenced by models from institutions like Peking Union Medical College Hospital and Fudan University Shanghai Cancer Center. Programs include vaccination campaigns conducted with the Chinese Center for Disease Control and Prevention, initiatives to control non-communicable diseases in partnership with the Chinese Center for Disease Control and Prevention and the World Health Organization, and integration of Traditional Chinese medicine services alongside modern biomedical care. It has overseen pilot reforms in health insurance coordination involving the National Healthcare Security Administration and promoted telemedicine linked to platforms developed by companies such as Ping An Healthcare and collaborations with universities like Tsinghua University.

Public Health Emergencies and Response

The commission played a central role in coordinating responses to outbreaks including the 2019–20 coronavirus pandemic in mainland China and previous emergencies such as the 2009 H1N1 pandemic in China and the Severe acute respiratory syndrome outbreak (2002–2004). It works closely with the Chinese Center for Disease Control and Prevention, provincial health commissions, and municipal agencies like the Hubei Provincial Health Commission during crises. Emergency response mechanisms are informed by frameworks from the State Council (China) and have involved joint actions with the Ministry of Public Security (China) and the Civil Affairs Bureau for logistics, quarantine, and hospital construction such as the rapid deployment exemplified by Leishenshan Hospital.

International Cooperation

The commission engages in global health diplomacy through interactions with the World Health Organization, bilateral health agreements with ministries such as the United States Department of Health and Human Services and the Ministry of Health (Singapore), and participation in multilateral mechanisms including Belt and Road Initiative health projects. It coordinates international medical assistance teams dispatched to regions affected by disasters, working with entities like the United Nations and regional partners including the African Union and the Association of Southeast Asian Nations. Scientific collaborations extend to institutions such as the Harvard T.H. Chan School of Public Health, the London School of Hygiene & Tropical Medicine, and the Pasteur Institute on research, surveillance, and capacity building.

Criticisms and Controversies

The commission has faced scrutiny over transparency and information-sharing during emergent outbreaks, drawing critique from media outlets and researchers including those at The Lancet, Nature (journal), and academic groups at Peking University and Tsinghua University. Controversies have involved dispute over early reporting in the 2019–20 coronavirus pandemic in mainland China, interactions with international bodies like the World Health Organization, and debates on regulatory oversight of pharmaceuticals and vaccine safety after incidents involving firms such as Changchun Changsheng Biotechnology. There have also been discussions in forums involving the National People's Congress and civil society organizations about healthcare access, rural health disparities addressed by programs involving the New Rural Cooperative Medical Scheme, and reforms in public hospital governance.

Category:Health in the People's Republic of China